Strides Arcolab's generic hypertension drug gains FDA approval

02/9/2010 | Reuters

The FDA approved Strides Arcolab's generic version of Prometheus Laboratories' Trandate hydrochloride injection for treating blood pressure in severe hypertension. Strides' version, labetalol, was co-developed by Sagent Pharmaceuticals and is the third product to come out of their collaboration.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care